Head and neck
OrigAMI-5
A Phase 3 Open-Label Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, In Comparison with Standard of Care Platinum/Pembrolizumab/5-FU, in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
Trial overview
Clinical Area
Medical Oncology
Disease
Head and neck
Disease site
Head and neck
Study Phase
III
Trial Identifiers
Registration number: NCT07276399
GenesisCare Location(s)
Principal Investigator(s)